Bhvita Jani, research manager at the healthcare market analysis firm Signify Research, shares noteworthy happenings from the ECR expo floor.

The company is still riding the momentum of its technology being included in the 2021 American College of Cardiology/American Heart Association chest pain guidelines.

Radiology makes up the vast majority of FDA-cleared AI algorithms, but with minimal or no reimbursement, hospital administrators may ask whether AI’s value justifies its expense.

The FDA-approved tool works by reprioritizing CTPA exams to the top of a radiologist’s work list when the scan is positive for PE.

A popular marketer of handheld ultrasound devices has won FDA approval for an AI-enabled B-line quantification tool for use with patients suspected of having compromised lung function.

Radiology AI vendor Bot Image may market its prostate software not only for diagnosing cancer when suspected but also for performing prostate screenings.

Big Tech players have been investing in partnerships with large healthcare providers on AI endeavors for several years now. According to both sides in one such collaboration, the resulting synergy offers “immense potential” to improve patient access, care and outcomes.

AI clinical decision support was particularly popular among younger radiologists, experts wrote in Scientific Reports.